Convelo Therapeutics: Funding, Investors & Team (Sep 2026)
Convelo Therapeutics is developing a new class of medicines that unlock the regenerative capacity of the central nervous system. Convelo is pioneering approaches to regenerate the protective myelin coating around nerve cells that is lost in a wide array of neurological diseases including multiple sclerosis, pediatric leukodystrophies, traumatic injury and age-related pathologies such as Alzheimer’s. Convelo has identified key biological targets and a pipeline of drug candidates to provide novel and meaningful solutions for patients and their families.
Convelo Therapeutics has raised $10.8M across 1 funding round on record, the most recent an undisclosed round of $10.8M announced in Dec 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Convelo Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2022.
Convelo Therapeutics Funding Rounds
Convelo Therapeutics Founders and Leadership Team
Contact details for the Convelo Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Convelo Therapeutics Funding Compared to Other Biotechnology Startups
Convelo Therapeutics' latest round of $10.8M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Convelo Therapeutics in Biotechnology and Cleveland
Companies Similar to Convelo Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Convelo Therapeutics Funding FAQs
What does Convelo Therapeutics do?
Convelo Therapeutics is developing a new class of medicines that unlock the regenerative capacity of the central nervous system. Convelo is pioneering approaches to regenerate the protective myelin coating around nerve cells that is lost in a wide array of neurological diseases including multiple sclerosis, pediatric leukodystrophies, traumatic injury and age-related pathologies such as Alzheimer’s. Convelo has identified key biological targets and a pipeline of drug candidates to provide novel and meaningful solutions for patients and their families.
How much funding has Convelo Therapeutics raised?
Convelo Therapeutics has raised $10.8M across 1 round on record. The most recent is an undisclosed round of $10.8M announced in Dec 2022.
When did Convelo Therapeutics last raise funding?
Convelo Therapeutics' most recent funding round on record is an undisclosed round of $10.8M, announced in Dec 2022.
Who founded Convelo Therapeutics?
FundedIQ lists Paul Tesar (Founder) at Convelo Therapeutics.
Where is Convelo Therapeutics headquartered?
Convelo Therapeutics is based in Cleveland, Ohio, United States.
How many employees does Convelo Therapeutics have?
Convelo Therapeutics is in the 11-50 employee band.
How does Convelo Therapeutics' funding compare to other Biotechnology startups?
Convelo Therapeutics' latest round of $10.8M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Convelo Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Convelo Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.